secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2026-08-03T20:06:40+00:00
Accession:  0001232524-26-000044
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma Q2 2026: record revenue $1.2B (+16% YoY); raises FY2026 guidance to $4.60-$4.75B
--------------------------------------------------------------------------------

- Total revenues of $1.2B, a record, up 16% YoY; GAAP EPS $2.78, non-GAAP adjusted EPS $5.71.
- Xywav revenues +13% YoY with 525 net patient adds in Q2; Epidiolex revenues +16% YoY.
- Company raises 2026 revenue guidance to $4.60-$4.75B, reflecting double-digit growth from Xywav and epilepsy/oncology.
- FDA set PDUFA date of Aug 25, 2026 for zanidatamab sBLA in 1L GEA; BTD granted for HER2+ CRC.
- Cash from operations $824M in first half 2026; strong balance sheet supports pipeline and launches.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/0001232524-26-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/jazz-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001232524-26-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer